{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:18:18Z","timestamp":1791019098437,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,2,20]],"date-time":"2003-02-20T00:00:00Z","timestamp":1045699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In preclinical systems, calcitriol, the natural vitamin D receptor (VDR) ligand, has been found to demonstrate antiproliferative effects, although concentrations &gt; 1 nM are required. Unlike daily dosing, weekly administration of oral calcitriol can safely achieve such blood calcitriol concentrations. This study sought to define the long\u2010term toxicity of this regimen and measure its effect on serum prostate specific antigen (PSA) levels in patients with hormone\u2010na\u00efve prostate carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with a rising serum PSA after prostatectomy and\/or radiation and no prior systemic therapy for prostate carcinoma recurrence maintained a reduced calcium diet and received calcitriol 0.5 \u03bcg\/kg orally once each week until a maximum of a four\u2010fold increase in the PSA.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twenty\u2010two patients received treatment for a median of 10 months (range, 2\u201325+ months). Treatment was well tolerated with no Grade \u2265 3 toxicity and no hypercalcemia or renal calculi. No patient had a PSA response (50% reduction confirmed 4 weeks later). Three patients (14%, 95% CI 0\u201328%) had confirmed reductions in the PSA ranging from 10% to 47%. Statistically significant increases in the PSA doubling time (PSADT) were seen in three additional patients and no patient had a shorter PSADT after starting treatment. For the entire study population, the median PSADT increased from 7.8 months to 10.3 months (<jats:italic>P<\/jats:italic> = 0.03 by Wilcoxon signed rank test).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Weekly high\u2010dose calcitriol was found to be safe. The primary efficacy endpoint of 50% reduction in the serum PSA was not achieved with this therapy. Randomized studies are needed to further examine the impact of this therapy on prostate carcinoma progression. Cancer 2003;97:1217\u201324. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11179<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11179","type":"journal-article","created":{"date-parts":[[2003,2,24]],"date-time":"2003-02-24T08:59:46Z","timestamp":1046077186000},"page":"1217-1224","source":"Crossref","is-referenced-by-count":93,"title":["High\u2010dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma"],"prefix":"10.1002","volume":"97","author":[{"given":"Tomasz M.","family":"Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Lemmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Henner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,2,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1013"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0094-0143(21)01375-6","article-title":"Prostate\u2010specific antigen for staging prior to surgery and for early detection of recurrence after surgery","volume":"17","author":"Lange PH","year":"1990","journal-title":"Urol Clin North Am."},{"key":"e_1_2_6_5_2","first-page":"1035","article-title":"Consensus statement: guidelines for PSA following radiation therapy","volume":"37","author":"American Society for Therapeutic Radiology and Oncology Consensus Panel","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"e_1_2_6_6_2","first-page":"141","article-title":"Radiation therapy for a rising PSA level after radical prostatectomy","volume":"17","author":"Tiguert R","year":"1999","journal-title":"Semin Urol Oncol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1155"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C"},{"key":"e_1_2_6_9_2","first-page":"165","article-title":"Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies","volume":"7","author":"Bryar DP","year":"1988","journal-title":"NCI Monograph."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1642"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(96)03974-3"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(96)00030-1"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.132.5.7682937"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/endo.136.1.7530193","article-title":"Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25\u2010dihydroxyvitamin D3","volume":"136","author":"Skowronski RJ","year":"1995","journal-title":"Endocrinology."},{"key":"e_1_2_6_16_2","first-page":"805","article-title":"Antiproliferative effects of 1,25\u2010dihydroxyvitamin D3 on primary cultures of human prostatic cells","volume":"54","author":"Peehl DM","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_6_17_2","first-page":"1077","article-title":"Human prostate cancer cells: inhibition of proliferation by vitamin D analogs","volume":"14","author":"Schwartz GG","year":"1994","journal-title":"Anticancer Res."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80221-0"},{"key":"e_1_2_6_19_2","first-page":"779","article-title":"A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice","volume":"60","author":"Polek TC","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63236-1"},{"key":"e_1_2_6_21_2","first-page":"1339","article-title":"A Phase I trial of calcitriol (1,25\u2010dihydroxycholecalciferol) in patients with advanced malignancy","volume":"5","author":"Smith DC","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010615)91:12<2431::AID-CNCR1278>3.0.CO;2-3"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-1-91"},{"key":"e_1_2_6_26_2","first-page":"315","volume-title":"Estimation of area under the curve biopharmaceutics and clinical pharmacokinetics","author":"Gibaldi M","year":"1984"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)32394-7"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940715)74:2<670::AID-CNCR2820740220>3.0.CO;2-8"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64238-1"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650100803"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0180037"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11179","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:43:13Z","timestamp":1760265793000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,20]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1002\/cncr.11179"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11179","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,20]]}}}